-
Exactly 1397 antiretroviral (ARV) naïve patients initiating ARVs, as part of a CPCRA-sponsored clinical trial (FIRST trial), were followed for a median of five years.
-
The utility of surveillance screening for MRSA on hospital admission remains controversial. Three recently published clinical trials attempt to assess the role of MRSA surveillance.
-
All patients admitted to the ICU at the Air Force Theater Hospital (Balad, Iraq) were followed prospectively for the development of VAP. There were 475 patients admitted to the ICU from May 2006 through August 2006.
-
-
In this Issue: Pioglitazone and heart disease; ARBs manufacturers spend millions to show the non-inferiority of their products compared to less expensive, generic ACE inhibitors; some athletes turn to growth hormone because it is difficult to detect; FDA Actions
-
This study of a very large prospective series of cardiac arrests in over 500 US hospitals found that survival rates were lower during nights and weekends, differences that persisted despite adjustments for patient, resuscitation event, and hospital characteristics.
-
The risk of venous thromboembolism was double in users of a transdermal contraceptive as compared to users of an oral contraceptive with a 35 mcg ethinyl estradiol component. Warning: no abstract skimming — it's worth your while to keep reading!
-
This multi-center, randomized, double-blind clinical trial demonstrated that the addition of vasopressin to patients receiving norepinephrine for management of septic shock had no effect on mortality when compared to increasing the norepinephrine dose.
-
Intravascular volume expansion has long been advised as an effective temporizing technique for patients with cardiac tamponade prior to drainage of the fluid, but there is little data supporting this practice.
-
Vernakalant is a new investigational anti-arrhythmic drug. The compound is relatively selective, blocking the early-activating potassium channel and the frequency-dependent sodium channel; it has a half-life of two to three hours.
